India's Piramal Pharma rises on successful completion of USFDA probe
** Shares of Piramal Pharma PIRM.NS rise as much as 3.43% to
70.80 rupees
** Co says USFDA successfully closes its good manufacturing
practices (GMP) inspection of its Digwal facility
** FDA has concluded the probe with zero Form 483
observations - co
** Care Ratings on Friday assigned "CARE AA-, stable" rating
to PIRM
** ~1.25 mln shares change hands in early trade - Refinitiv
data
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463))
Recent news on Piramal Pharma (Mumbai)
See all newsBrief: Piramal Pharma Receives Permanent Revocation Of Closure Order For Dahej Site
Brief: Piramal Pharma Solutions Announces Partnership With Botanix To Support Drug Substance Development
Brief: Piramal Pharma Announces Successful Closure Of Us FDA Inspection At Digwal Facility
India's Piramal Pharma eyes complex drug demand for earnings boost, chair says
Brief: Piramal Pharma Says Closure Of US FDA Inspection At Manufacturing Facility At Lexington